COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME accredited program entitled Advances In Wound Therapy: Understanding Differences Between Cellular And Acellular Therapies in the Treatment of Chronic Wounds at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
The supplement features a discussion on available clinical evidence from trials conducted in patients with diabetic foot ulcers (DFUs). The authors, Dr. Lawrence Lavery, Professor of Surgery, University of Texas Southwestern and Dot Weir, RN, CWON, CWS, assign a high-quality, successful designation to only 4 trials in the space including Grafix®, Dermagraft®, Apligraf®, and Graftjacket® as these are the only trials that were multi-center, randomized, controlled trials. Furthermore, the authors note that Grafix is the only placental membrane product for chronic wounds supported by multicenter, randomized, controlled, clinical evidence.
Help employers find you! Check out all the jobs and post your resume.
